Top Tweets for #ENDRMC
Thank you so much @TiansterZhang! We are excited to have this biology-driven trial open for our patients with #RenalMedullaryCarcinoma 👉 https://t.co/fHR5LxMFPt #endRMC
@PavlosMsaouel @MDAndersonnews puts his passion and life work behind extending survival for #renalmedullary cancers. Congrats on launching the newest IIT w a trop2 ADC for RMC!
🚀 Now enrolling @UTMDAnderson: STaRMC trial testing sacituzumab tirumotecan in SMARCB1-deficient #RenanMedullaryCarcinoma
👉 https://t.co/fHR5LxMFPt RMC outcomes have improved but we still lose too many. A key step to #EndRMC. #MsaouelLab #RareCancers #kidneycancer @KidneyCancer
1/5 🧵 New paper out today in the @SNM_MI Journal of Nuclear Medicine: FDG PET/CT may change how we stage #RenalMedullaryCarcinoma (RMC) and help patients get the right treatment faster: https://t.co/7ebeFvw95M #endRMC #MsaouelLab
Definitely a big day for #RenalMedullaryCarcinoma with our new standard of care therapy to be presented that has helped double the median survival of this disease in recent years. #endRMC #Kidneycancer
Late night post as I board my flight for #ASCO26…looking to Monday! Feels like it could be a BIG day for #kidneycancer, especially non clear cell. Excited to hear more about CBM588 esp since @SWOG @PBarataMD @DrVaishampayan just launched BIOFRONT. Then can’t wait to hear @PavlosMsaouel’s latest on #renalmedullarycarcinoma. Rounding it out with @DrDarrenFeldman on a non-clear cell RCC trial results. It will be a jam packed morning for sure!
Thank you for highlighting @neerajaiims. 🙏Excited to share these results with the #ASCO26 community. #endRMC #kidneycancer #RenalMedullaryCarcinoma
Ab#4520 @ASCO #ASCO26 by @PavlosMsaouel👉 https://t.co/uWJK7LTPE2👉Remarkable clinical activity of EGFR blockade (panitumumab) in SMARCB1-deficient renal medullary mRCC #kidneycancer👉Median PFS 5.8 mo & median OS 9.5 mo👇@NikiZacharias @BradMcG04 @OncoAlert @urotoday @kidneycan
1/5 New in @CCR_AACR: Results of the 1st prospective trial of a targeted agent in #SMARCB1-deficient #RenalMedullaryCarcinoma (RMC). We tested ixazomib + gemcitabine + doxorubicin in 30 patients https://t.co/LyGS55EfcV #endRMC #MsaouelLab
Reflections on the current state of the art in #RenalMedullaryCarcinoma management and therapeutic targets on our way to improve median survival to 5 years by 2030: https://t.co/eGNRn9zZsD #EndRMC @renalmedullary #Kidneycancer
Wrapped up my first ASCO GU and was grateful to present our work on unique germline HRR mutations in RCCU-MP, which was honored with a Merit Award. Grateful to @PavlosMsaouel for the opportunity #EndRMC #GU26 @ConquerCancerFd @ASCO
Onwards to get #RenalMedullaryCarcinoma median survival to 5 years before the end of 2030 and to ultimately eradicate this cruel disease! #EndRMC #kidneycancer
This summary on the rapid improvement in survival rate for #RMC patients understates the impact @PavlosMsaouel has had on these patients especially on #RareDiseaseDay2026. 4 months ➡️ 13 months ➡️ 2 years is PHENOMENAL. #GU26
Congratulations to @panos_konto for his #GU26 Merit Award during his IM internship @UTSWInternalMed for his work on #RenalMedullaryCarcinoma germline risk factors. #EndRMC @KidneyCancer @kcCURE @kidneycan @RmcAlliance
Onwards 🔬 #EndRMC
Honored to receive this award and deeply grateful for the continued mentorship from @PavlosMsaouel. Looking forward to attending my first @ASCO #GU26 and sharing our work. #EndRMC #rarecancers
Honored to receive this award and deeply grateful for the continued mentorship from @PavlosMsaouel. Looking forward to attending my first @ASCO #GU26 and sharing our work. #EndRMC #rarecancers
We are pleased to announce the recipients of 2026 Genitourinary Cancers Symposium Merit Awards selected for presentation at the @ASCO Genitourinary Cancers Symposium, February 26-28. Congrats!
See the full list of recipients here: https://t.co/81HbuQDrzX
#GU26 #ResearchConquersCancer #CancerResearch
Thank you for the thoughtful summary. We were struck by how consistently rapid progression paradoxically occurred in this dedicated #RenalMedullaryCarcinoma cohort. The correlative and preclinical data helped move the story to an actionable biology informing next steps to #endRMC
6/Critical mechanistic insight in #RMC with Soeung et al. (@NatComms). This phase II trial of nivolumab plus ipilimumab was halted for futility as all 10 patients experienced rapid progression. Single-cell RNA sequencing revealed immune checkpoint therapy triggered interferon-γ-mediated "myeloid mimicry" in tumor cells via the CEBPB/p300 axis, promoting proliferation and hyperprogression. Pharmacologic p300 inhibition restored sensitivity to immunotherapy in preclinical models, identifying an adaptive resistance mechanism and rational therapeutic strategy for RMC and potentially other aggressive malignancies. @MDAndersonNews -Bravo @PavlosMsaouel team!
https://t.co/ZrMUEBlyda
1/5 Our new @NatureComms study reports the first-ever dedicated clinical trial for #RenalMedullaryCarcinoma (RMC): phase II trial of #nivolumab + #ipilimumab and what it taught us about hyperprogression to immunotherapy: https://t.co/q1UwZr8L3i #endRMC #MsaouelLab @MDAndersonNews
Thank you for the kind words. It is a privilege for our team to take on this unmet need. The momentum will continue to expand globally until #RenalMedullaryCarcinoma is completely eradicated. #endRMC
@sciqst @PavlosMsaouel @CellRepMed @BostonGeneCorp @d_shapiro1 @PGrivasMDPhD @montypal @VivekSubbiah @OncHahn @JadChahoud @KidneyCancer @kidneycan @neerajaiims @DrJeffreyGraham I have been a patient advocate for other kidney cancer patients and had known do little about any recent work against this terrible variant—until I knew of work by Msaouel and his colleagues. He has opened a door of hope for all RMC patients. With gratitude from those patients
Impactful effort between @PavlosMsaouel and @BostonGeneCorp in a deadly rare cancer #endRMC !! #rarecancers
1/5 Our new @CellRepMed study delivers the largest #RenalMedullaryCarcinoma molecular profiling via @BostonGeneCorp + translational testing designed to uncover targetable vulnerabilities: https://t.co/TGksd8oLWM #MsaouelLab #endRMC #rarecancers
1/5 Our new @CellRepMed study delivers the largest #RenalMedullaryCarcinoma molecular profiling via @BostonGeneCorp + translational testing designed to uncover targetable vulnerabilities: https://t.co/TGksd8oLWM #MsaouelLab #endRMC #rarecancers
Practical lifestyle notes (hydration, warm-up/cool-down) to maximize exercise benefits, and serum biomarkers in clinical practice (CA-125) and emerging (ctDNA) for patients with #RenalMedullaryCarcinoma https://t.co/jQazFj056z @GUOncologyNow #EndRMC #rarecancers #kidneycancer
When to suspect that a patient has #RenalMedullaryCarcinoma @GUOncologyNow #kidneycancer #endRMC https://t.co/bGOntvqZuJ
Discussing the latest management approaches for #renalmedullarycarcinoma #endRMC #kidneycancer @GUOncologyNow https://t.co/A474Vh41Su
Last Seen Hashtags on Sotwe
扫楼打胶
Seen from Malaysia
momsonn
nsfwanimation
Seen from United States
tantenakal
Seen from Indonesia
ai hijab
Seen from Indonesia
georgiaharrison
Seen from United Kingdom
ควยพม่า
Seen from Thailand
desi
Seen from United Kingdom
teenage #nolimit #teenagegirls
Seen from Brazil
metrocruisinggay
Seen from India
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.7M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.9M followers
Taylor Swift
@taylorswift13
82.8M followers
Lady Gaga
@ladygaga
74.3M followers
Virat Kohli
@imvkohli
71.8M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.7M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers